{
  "identity": {
    "bacteriumName": "Klebsiella species (oxytoca, pneumoniae, variicola)",
    "aliases": [
      "Klebsiella oxytoca",
      "Klebsiella pneumoniae",
      "Klebsiella variicola"
    ],
    "lastUpdated": "2025-01-08",
    "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
    "classification": {
      "gramStain": "Gram-negative",
      "morphology": "Bacilli",
      "respiration": "Facultative anaerobe",
      "notes": [
        "Fermentative"
      ]
    },
    "strainDetails": [
      {
        "type": "Complex",
        "value": "Klebsiella pneumoniae complex",
        "notes": "Includes K. pneumoniae and K. variicola."
      },
      {
        "type": "Phenotype",
        "value": "Hypermucoviscous Klebsiella",
        "notes": "Increasingly recognized strains that can cause metastatic infections, like liver abscesses, in healthy hosts."
      }
    ],
    "biochemicalTests": "Gram-negative rod, non-motile, encapsulated, lactose fermenter (mucoid pink colonies on MacConkey agar), VP +, citrate +. K. oxytoca is indole +, while K. pneumoniae and K. variicola are indole –."
  },
  "clinicalProfile": {
    "summary": "Klebsiella species cause a variety of infections, ranging from uncomplicated UTIs to life-threatening infections of the abdomen, skin/soft tissue, lungs, and CNS in both normal and immunocompromised hosts.",
    "pathophysiologyPearls": [
      "There is increasing recognition of hypermucoviscous strains that can cause metastatic infections, such as liver abscesses, even in healthy hosts."
    ],
    "keySignsAndSymptoms": [],
    "clinicalSyndromes": [
      {
        "syndromeName": "Urinary Tract Infections (UTI)",
        "description": "Can be uncomplicated or complicated."
      },
      {
        "syndromeName": "Intra-abdominal Infections",
        "description": ""
      },
      {
        "syndromeName": "Skin and Soft Tissue Infections",
        "description": ""
      },
      {
        "syndromeName": "Pneumonia",
        "description": "Infection of the lungs."
      },
      {
        "syndromeName": "Central Nervous System (CNS) Infections",
        "description": "e.g., meningitis, brain abscess."
      },
      {
        "syndromeName": "Liver Abscess",
        "description": "Particularly associated with hypermucoviscous strains."
      }
    ],
    "stagesOfIllness": [],
    "highRiskPopulations": [
      "Immunocompromised hosts",
      "Healthy hosts (for infections caused by hypermucoviscous strains)"
    ],
    "transmissionVectors": [],
    "prognosisNotes": []
  },
  "resistanceProfile": {
    "groupIntrinsicResistance": [],
    "intrinsicResistance": [],
    "majorMechanisms": [
      {
        "mechanismName": "Extended-Spectrum Beta-Lactamases (ESBLs)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "A common resistance mechanism conferring resistance to third-generation cephalosporins and aztreonam. Piperacillin-tazobactam is not recommended for serious infections caused by ESBL producers, despite potential in vitro susceptibility, due to clinical failures."
      },
      {
        "mechanismName": "Klebsiella pneumoniae carbapenemase (KPC)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "A serine-based carbapenemase that confers resistance to carbapenems and most other beta-lactams."
      },
      {
        "mechanismName": "Metallo-beta-lactamase (MBL)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "A type of carbapenemase that confers resistance to carbapenems and newer beta-lactamase inhibitors like ceftazidime-avibactam and meropenem-vaborbactam."
      },
      {
        "mechanismName": "OXA-48-like enzymes",
        "mechanismType": "Enzymatic Inactivation",
        "description": "A type of carbapenemase; if detected, meropenem-vaborbactam may not be effective and should be reported as resistant."
      }
    ],
    "clinicalAlerts": [
      {
        "alertTitle": "Carbapenemase Production and Cefepime Reporting",
        "details": "If carbapenemase production is identified in a Klebsiella isolate, any cefepime results indicating susceptibility should be suppressed or edited and reported as resistant."
      },
      {
        "alertTitle": "Piperacillin-Tazobactam for ESBL",
        "details": "Piperacillin-tazobactam is not recommended for serious infections caused by ESBL-producing Klebsiella despite potential in vitro susceptibility due to risk of clinical failures."
      }
    ]
  },
  "treatment": {
    "generalNotes": [
      "Recommendations are for moderately severe or severe infections, especially where resistance is a concern.",
      "For uncomplicated or less severe infections by susceptible strains, options include Amoxicillin-clavulanate, fluoroquinolones, and 2nd/3rd gen cephalosporins.",
      "TMP-SMX is an option if the isolate is susceptible, but empiric use is limited by high rates of resistance.",
      "Nitrofurantoin and oral Fosfomycin are options for uncomplicated UTIs."
    ],
    "drugsToAvoid": [
      {
        "drugOrClass": "Piperacillin-tazobactam",
        "condition": "Serious infections caused by ESBL-producers",
        "reason": "Risk of clinical failure despite in vitro susceptibility."
      }
    ],
    "adjunctiveTherapies": [],
    "regimens": [
      {
        "context": {
          "type": "Empiric",
          "condition": "Suspected Klebsiella spp. infection",
          "patientPopulation": [
            "Local ESBL rate <10%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  },
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 4 hours."
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "bid",
                    "comments": ""
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Empiric",
          "condition": "Suspected Klebsiella spp. infection",
          "patientPopulation": [
            "Local ESBL rate >10%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Non-ESBL Producer",
          "patientPopulation": [
            "Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  },
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 4 hours."
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "bid",
                    "comments": ""
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  { "drugName": "Cefazolin", "dose": "1 gm", "route": "IV", "frequency": "q8h", "comments": "" },
                  { "drugName": "TMP-SMX", "dose": "10 mg/kg/day (TMP component)", "route": "IV/PO", "frequency": "in 2-3 divided doses", "comments": "" },
                  { "drugName": "Amoxicillin-clavulanate", "dose": "1.2-2.4 gm", "route": "IV", "frequency": "q8h", "comments": "Where available" }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "ESBL Producer",
          "patientPopulation": [
            "Resistant to ESBL-panel antibiotics but susceptible to carbapenems"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "For serious infections, consider 2 gm infused over 3 hours q8h."
                  },
                  {
                    "drugName": "Imipenem",
                    "dose": "500 mg",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Carbapenem-sparing Alternative (Non-Urinary Source)",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  { "drugName": "Ceftolozane-tazobactam", "dose": "1.5 gm", "route": "IV", "frequency": "q8h", "comments": "Administer over 3 hrs." },
                  { "drugName": "Ceftazidime-avibactam", "dose": "2.5 gm", "route": "IV", "frequency": "q8h", "comments": "Infused over 3 hrs." }
                ]
              }
            ]
          },
          {
            "preference": "Carbapenem-sparing Alternative (Urinary Tract Source)",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  { "drugName": "Temocillin", "dose": "2 gm", "route": "IV", "frequency": "q12h", "comments": "Where available." },
                  { "drugName": "Fosfomycin IV", "dose": "6 gm", "route": "IV", "frequency": "q8h", "comments": "Infuse over 60 minutes. Where available." }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "KPC Producer",
          "patientPopulation": [
            "Resistant to carbapenems but susceptible to newer beta-lactamase inhibitors"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3 hrs."
                  },
                  {
                    "drugName": "Meropenem-vaborbactam",
                    "dose": "4 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3 hrs."
                  },
                  {
                    "drugName": "Imipenem-cilastatin-relebactam",
                    "dose": "1.25 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Infused over 30 min (for CrCl >90 mL/min)."
                  }
                ]
              }
            ],
            "notes": ["Infectious diseases consultation is strongly recommended."]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "MBL Producer",
          "patientPopulation": [
            "Resistant to carbapenems and newer beta-lactamase inhibitors"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 3 hours."
                  },
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Infuse over 2 hours. Must be given with Ceftazidime-avibactam."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Cefiderocol",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 3 hours."
                  }
                ]
              }
            ],
             "notes": ["Infectious diseases consultation is strongly recommended. Meropenem-vaborbactam plus Aztreonam may also be effective based on in vitro data."]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Carbapenemase (MBL) Producer with Complicated UTI",
          "patientPopulation": [],
          "isolateSource": "Urine"
        },
        "recommendations": [
          {
            "preference": "Salvage",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "4-7 days",
                "drugs": [
                  { "drugName": "Plazomicin", "dose": "15 mg/kg", "route": "IV", "frequency": "once daily", "comments": "May be an option for complicated UTI only." }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "laboratoryProfile": {
    "testingIndications": [],
    "methodologyNotes": [],
    "recommendedPanel": [],
    "specialTests": [],
    "reportingRules": [
      {
        "ruleType": "Exception",
        "drug": "Fosfomycin",
        "condition": "Isolate is not E. coli from a urinary tract source.",
        "details": "Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Klebsiella species."
      },
      {
        "ruleType": "Conditional",
        "drug": "Cefepime",
        "condition": "Carbapenemase production is identified.",
        "details": "Cefepime results indicating susceptibility should be suppressed or reported as resistant."
      },
      {
        "ruleType": "Conditional",
        "drug": "Meropenem-vaborbactam",
        "condition": "An OXA-48-like gene or enzyme is detected.",
        "details": "Results should be suppressed or reported as resistant as the isolate may not respond in vivo."
      },
      {
        "ruleType": "General",
        "drug": "All",
        "condition": "All Enterobacterales",
        "details": "Cascade reporting protocols are followed. Results for broader-spectrum agents are typically reported only if the isolate shows resistance to primary agents."
      }
    ],
    "antimicrobialBreakpoints": [
      {
        "tier": 1,
        "tierDescription": "Appropriate for routine, primary testing and reporting.",
        "agents": [
          {"agentName": "Ampicillin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "14–16 mm", "r_breakpoint": "≤ 13 mm"}, "mic": {"s_breakpoint": "≤ 8 µg/mL", "i_breakpoint": "16 µg/mL", "r_breakpoint": "≥ 32 µg/mL"}, "comments": ["Results of ampicillin testing can predict results for amoxicillin."]}]},
          {"agentName": "Amoxicillin-clavulanate", "breakpointSets": [{"condition": "Uncomplicated UTI only", "diskDiffusion": {"diskContent": "20/10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": null, "r_breakpoint": "≤ 17 mm"}, "mic": {"s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": "16/4 µg/mL", "r_breakpoint": "≥ 32/4 µg/mL"}, "comments": []}]},
          {"agentName": "Piperacillin-tazobactam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "100/10 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "21–24 mm", "r_breakpoint": "≤ 20 mm"}, "mic": {"s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": "16/4 µg/mL", "r_breakpoint": "≥ 32/4 µg/mL"}, "comments": []}]},
          {"agentName": "Gentamicin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL"}, "comments": []}]},
          {"agentName": "Tobramycin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "13–16 mm", "r_breakpoint": "≤ 12 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL"}, "comments": []}]},
          {"agentName": "Amikacin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 19 mm", "i_breakpoint": "17–18 mm", "r_breakpoint": "≤ 16 mm"}, "mic": {"s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 32 µg/mL"}, "comments": []}]},
          {"agentName": "Ciprofloxacin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "5 µg", "s_breakpoint": "≥ 26 mm", "i_breakpoint": "22–25 mm", "r_breakpoint": "≤ 21 mm"}, "mic": {"s_breakpoint": "≤ 0.25 µg/mL", "i_breakpoint": "0.5 µg/mL", "r_breakpoint": "≥ 1 µg/mL"}, "comments": []}]},
          {"agentName": "Levofloxacin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "5 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "17–20 mm", "r_breakpoint": "≤ 16 mm"}, "mic": {"s_breakpoint": "≤ 0.5 µg/mL", "i_breakpoint": "1 µg/mL", "r_breakpoint": "≥ 2 µg/mL"}, "comments": []}]},
          {"agentName": "Trimethoprim-sulfamethoxazole", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "1.25/23.75 µg", "s_breakpoint": "≥ 16 mm", "i_breakpoint": "11–15 mm", "r_breakpoint": "≤ 10 mm"}, "mic": {"s_breakpoint": "≤ 2/38 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4/76 µg/mL"}, "comments": []}]}
        ]
      },
      {
        "tier": 2,
        "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules.",
        "agents": [
          {"agentName": "Cefuroxime (Parental)", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "15–22 mm", "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8–16 µg/mL", "r_breakpoint": "≥ 32 µg/mL"}, "comments": []}]},
          {"agentName": "Cefepime", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "19–24 mm", "r_breakpoint": "≤ 18 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8 µg/mL", "r_breakpoint": "≥ 16 µg/mL"}, "comments": ["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},
          {"agentName": "Ertapenem", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 22 mm", "i_breakpoint": "19–21 mm", "r_breakpoint": "≤ 18 mm"}, "mic": {"s_breakpoint": "≤ 0.5 µg/mL", "i_breakpoint": "1 µg/mL", "r_breakpoint": "≥ 2 µg/mL"}, "comments": []}]},
          {"agentName": "Imipenem", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm"}, "mic": {"s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL"}, "comments": []}]},
          {"agentName": "Meropenem", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm"}, "mic": {"s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL"}, "comments": []}]}
        ]
      },
      {
        "tier": 3,
        "tierDescription": "Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.",
        "agents": [
          {"agentName": "Cefiderocol", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 20 mm", "i_breakpoint": "9–15 mm", "r_breakpoint": "≤ 8 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL"}, "comments": []}]},
          {"agentName": "Ceftazidime-avibactam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30/20 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": null, "r_breakpoint": "≤ 20 mm"}, "mic": {"s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 16/4 µg/mL"}, "comments": ["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},
          {"agentName": "Imipenem-relebactam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "10/25 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "21–24 mm", "r_breakpoint": "≤ 20 mm"}, "mic": {"s_breakpoint": "≤ 1/4 µg/mL", "i_breakpoint": "2/4 µg/mL", "r_breakpoint": "≥ 4/4 µg/mL"}, "comments": ["These breakpoints apply to Klebsiella species as they are Enterobacterales but not Morganellaceae."]}]},
          {"agentName": "Meropenem-vaborbactam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "20/10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 4/8 µg/mL", "i_breakpoint": "8/8 µg/mL", "r_breakpoint": "≥ 16/8 µg/mL"}, "comments": ["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},
          {"agentName": "Plazomicin", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 2 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4 µg/mL"}, "comments": []}]}
        ]
      },
      {
        "tier": 4,
        "tierDescription": "May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",
        "agents": [
          {"agentName": "Aztreonam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "18–20 mm", "r_breakpoint": "≤ 17 mm"}, "mic": {"s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8 µg/mL", "r_breakpoint": "≥ 16 µg/mL"}, "comments": []}]},
          {"agentName": "Ceftriaxone", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 26 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm"}, "mic": {"s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL"}, "comments": []}]},
          {"agentName": "Ceftazidime", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "18–20 mm", "r_breakpoint": "≤ 17 mm"}, "mic": {"s_breakpoint": "≤ 8 µg/mL", "i_breakpoint": "16 µg/mL", "r_breakpoint": "≥ 32 µg/mL"}, "comments": []}]},
          {"agentName": "Ceftolozane-tazobactam", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": "30/10 µg", "s_breakpoint": "≥ 22 mm", "i_breakpoint": "19–21 mm", "r_breakpoint": "≤ 18 mm"}, "mic": {"s_breakpoint": "≤ 2/4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4/4 µg/mL"}, "comments": []}]},
          {"agentName": "Colistin or Polymyxin B", "breakpointSets": [{"condition": "Standard", "diskDiffusion": {"diskContent": null, "s_breakpoint": null, "i_breakpoint": null, "r_breakpoint": null}, "mic": {"s_breakpoint": "≤ 2 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4 µg/mL"}, "comments": ["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}
        ]
      },
      {
        "tier": 5,
        "tierDescription": "Urine Only Tier",
        "agents": [
          {"agentName": "Cefazolin", "breakpointSets": [{"condition": "Uncomplicated UTI only", "diskDiffusion": {"diskContent": "30 µg", "s_breakpoint": "≥ 15 mm", "i_breakpoint": null, "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 32 µg/mL"}, "comments": ["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},
          {"agentName": "Nitrofurantoin", "breakpointSets": [{"condition": "Urine Only", "diskDiffusion": {"diskContent": "300 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "15–16 mm", "r_breakpoint": "≤ 14 mm"}, "mic": {"s_breakpoint": "≤ 32 µg/mL", "i_breakpoint": "64 µg/mL", "r_breakpoint": "≥ 128 µg/mL"}, "comments": []}]},
          {"agentName": "Fosfomycin", "breakpointSets": [{"condition": "Urine Only", "diskDiffusion": {"diskContent": "200 µg", "s_breakpoint": "≥ 16 mm", "i_breakpoint": "13–15 mm", "r_breakpoint": "≤ 12 mm"}, "mic": {"s_breakpoint": "≤ 64 µg/mL", "i_breakpoint": "128 µg/mL", "r_breakpoint": "≥ 256 µg/mL"}, "comments": ["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Klebsiella."]}]}
        ]
      }
    ]
  },
  "additionalInformation": {
    "diagnosticNotes": {
      "summary": "",
      "biosafetyWarning": "",
      "methods": []
    },
    "preventionAndScreening": [],
    "treatmentLifecycle": [],
    "antimicrobialStewardship": [
      "Reserve carbapenems for ESBL-producing strains or for mixed anaerobic/aerobic infections.",
      "Reserve Ceftazidime-avibactam, Imipenem-relebactam, and Meropenem-vaborbactam for documented carbapenemase-producing infections."
    ],
    "drugSpecificPearls": [
      {
        "drugName": "Ceftazidime-avibactam + Aztreonam",
        "pearl": "This combination is recommended for metallo-beta-lactamase (MBL) producers because Aztreonam is not hydrolyzed by MBLs, and avibactam protects Aztreonam from other co-produced beta-lactamases like ESBLs or AmpC."
      },
      {
        "drugName": "Cefiderocol",
        "pearl": "FDA-approved for complicated UTIs with limited alternatives. In a key trial, 28-day mortality was not statistically different between cefiderocol and the best available therapy."
      },
      {
        "drugName": "Ceftazidime-avibactam",
        "pearl": "An observational study showed this drug was superior to Colistin for treating carbapenem-resistant Enterobacterales infections."
      },
      {
        "drugName": "Meropenem + Polymyxin",
        "pearl": "Combination therapy with Meropenem plus a polymyxin is not recommended for KPC producers based on a failed RCT, though the trial was underpowered for Enterobacterales."
      }
    ],
    "guidelineReferences": []
  }
}
